Skip to main content
Lê Hoàn Prosthetics & Orthotics

Orthoses

Marfan syndrome – a cause of scoliosis: a summary of the scientific evidence

Marfan syndrome is an inherited connective-tissue disorder caused by FBN1 variants. Its greatest danger is aortic dilatation and dissection, but about 6 in 10 patients also develop scoliosis that progresses faster and responds less to bracing than idiopathic scoliosis. This article summarises diagnosis, treatment and the role of orthotics.

Marfan syndrome – a cause of scoliosis: a summary of the scientific evidence

Marfan syndrome is an inherited disorder of connective tissue – the tissue that acts as a “scaffold” for blood vessels, ligaments, joint capsules and the eye. People with Marfan are often tall and slim, with long limbs and fingers and loose joints; many also have scoliosis, a sunken chest and flat feet.

For an orthotics clinic Marfan matters for two reasons: scoliosis in Marfan is harder to treat than idiopathic scoliosis, and a child with scoliosis and a Marfan-like build should be referred early for a heart check – because the greatest danger of the disease is in the aorta. Every figure has a source; the reference list at the end links to PubMed.

Quick summary

TopicKey pointSource
CauseVariants in FBN1 (encoding fibrillin-1), autosomal dominant; about 25% are new mutationsMilewicz 2021
Prevalence6.5 per 100,000 (Denmark); median age at diagnosis 19Groth 2015
DiagnosisRevised Ghent nosology 2010: aortic root dilatation and ectopia lentis are the cardinal featuresLoeys 2010
Greatest dangerAortic disease raises the risk of death enormously (HR 194.6)Groth 2018
MedicationAngiotensin receptor blockers (ARB) roughly halve the rate of aortic root enlargement; beta blockers have a similar effectPitcher 2022
SurgeryAortic root replacement at a diameter ≥ 5.0 cm (≥ 4.5 cm if high risk)ACC/AHA 2022
ScoliosisAbout 63% of patients; bracing succeeded in only about 17% in a 2000 studySponseller 1995, 2000

1. How does the disease arise?

It is caused by pathogenic variants in FBN1 on chromosome 15. FBN1 encodes fibrillin-1, the main component of the microfibrils that scaffold elastic fibres in the aortic wall, ligaments, periosteum and the suspensory ligament of the lens. Inheritance is autosomal dominant: an affected person has a 50% chance of passing it to each child. However, about 25% of patients carry a new mutation – their parents are unaffected – so “no one in the family has it” does not rule out Marfan (Milewicz, Nat Rev Dis Primers 2021).

Fibrillin-1 also keeps the signalling molecule TGF-β in an inactive form. The mouse study by Habashi and colleagues (Science 2006) showed that aortic aneurysm was linked to increased TGF-β signalling and could be prevented with losartan, an angiotensin receptor blocker. This opened the way to drug trials in humans (section 5).

Why does the aorta keep widening? By Laplace’s law, wall tension rises with pressure and radius. In Marfan the elastic network of the aortic wall is fragmented, so the wall is weak: the vessel widens → wall tension rises → the vessel widens further. Treatment therefore aims to reduce the load (medication, avoiding sudden strain) and to replace the segment before it reaches a dangerous size.

Musculoskeletal system: fibrillin-1 is present in periosteum, ligaments and joint capsules. Long bones overgrow, ligaments are lax, joints are hypermobile – the passive support of the spine and the foot arch weakens, favouring scoliosis, chest deformity and flat feet.

2. Features by organ system

SystemFeaturesData from studies
CardiovascularAortic root dilatation, aortic dissection, mitral valve prolapseAortic root dilated in 85–90% of patients (Milewicz 2021)
EyeEctopia lentis, high myopia, retinal detachmentAbout 60% develop ectopia lentis during life (Milewicz 2021)
SpineScoliosis, thoracolumbar kyphosis, spondylolisthesisAbout 63% have scoliosis (Sponseller 1995); Danish registry: 1 in 6 registered with scoliosis, 36.7 times the population risk (Andersen 2022)
DuraLumbosacral dural ectasiaPresent in most patients on MRI (Fattori, Lancet 1999)
ChestPectus excavatum (often asymmetric), pectus carinatum1 in 11 registered with a pectus deformity (Andersen 2022)
Limbs and feetArm span/height > 1.05, long fingers, hypermobile joints, flat feet, protrusio acetabuli1 in 6 with a foot deformity, mainly flat feet (Andersen 2022)
How to read this figure: left – the thumb sign (the thumb folded into the palm projects beyond the edge of the hand) and the wrist sign (thumb and little finger overlap when wrapped around the wrist), both reflecting long fingers and lax joints; centre – a sunken chest (pectus excavatum); right – an enlarged aortic root. These are features of the Ghent 2010 diagnostic score. Image: dungcuchinhhinh.vn.
How to read this figure: left – the thumb sign (the thumb folded into the palm projects beyond the edge of the hand) and the wrist sign (thumb and little finger overlap when wrapped around the wrist), both reflecting long fingers and lax joints; centre – a sunken chest (pectus excavatum); right – an enlarged aortic root. These are features of the Ghent 2010 diagnostic score. Image: dungcuchinhhinh.vn.

3. Diagnosis: the revised Ghent nosology (2010)

The criteria published by an international expert panel (Loeys and colleagues, J Med Genet 2010) make aortic root dilatation and ectopia lentis the two cardinal features. Aortic root size is expressed as a Z score (compared with people of the same age and body size).

Feature of the systemic score (maximum 20; ≥ 7 indicates systemic involvement)Points
Wrist and thumb sign (only one sign: 1 point)3
Pectus carinatum (pectus excavatum or chest asymmetry: 1 point)2
Hindfoot deformity (plain flat foot: 1 point)2
Pneumothorax2
Dural ectasia2
Protrusio acetabuli2
Reduced upper/lower segment ratio and increased arm span/height, no severe scoliosis1
Scoliosis or thoracolumbar kyphosis1
Reduced elbow extension1
Facial features (3 of 5)1
Skin striae1
Myopia > 3 dioptres1
Mitral valve prolapse1
  • Without a family history – Marfan is diagnosed with any of four situations: (1) aortic root Z ≥ 2 and ectopia lentis; (2) Z ≥ 2 and a pathogenic FBN1 variant; (3) Z ≥ 2 and a systemic score ≥ 7; (4) ectopia lentis and an FBN1 variant previously associated with aortic disease.
  • With a family history – any of three: ectopia lentis; systemic score ≥ 7; aortic root Z ≥ 2 (over 20 years) or Z ≥ 3 (under 20).
  • Applies only when there are no features of a similar disorder (Loeys-Dietz, Shprintzen-Goldberg, vascular Ehlers-Danlos).

How to read the table: add the points for the features present; 7 or more indicates systemic involvement, which counts towards the diagnosis together with aortic size. The original paper notes that the body-proportion thresholds were derived in white populations; reference data for Asians are lacking.

What this means for orthotists: four items of the score (wrist/thumb, chest, hindfoot, spine) are things we examine every day. A tall, slim child with scoliosis, long fingers, loose joints, myopia or a sunken chest should make us think of Marfan and refer for cardiology and genetics.

4. Prognosis: the burden lies in the aorta

  • Silverman and colleagues (Am J Cardiol 1995, 417 patients): median survival rose from 48 years (1972 data) to 72 years (1993) thanks to surgery and medical treatment.
  • Groth and colleagues (Am J Cardiol 2018, Danish nationwide registry): median lifespan 50 years versus 60 in controls; overall mortality 3.6 times higher, with aortic disease the main cause (HR 194.6).

Conclusion: early diagnosis, regular follow-up and timely preventive surgery extend life.

5. Medication: evidence from randomized trials

StudyDesignMain result
Cochrane, Koo 2017Systematic review of beta blockers vs no treatmentOnly 1 small randomized trial (70 people, propranolol); no proven reduction in dissection or death; low-quality evidence
Lacro, NEJM 2014608 children and young adults: atenolol vs losartanAfter 3 years the rate of change in aortic root Z score did not differ (p = 0.08); Z scores fell in both groups
AIMS, Mullen, Lancet 2019192 people aged 6–40, double-blind: irbesartan vs placeboAortic root dilatation 0.53 mm/year vs 0.74 mm/year (p = 0.030); well tolerated
MTT, Pitcher, Lancet 2022Individual-patient meta-analysis, 7 trials, 1,442 peopleARBs roughly halved the rate of increase in aortic root Z score, including in people on beta blockers; beta blockers had a similar effect

How to read the table: all trials measured the rate of aortic enlargement – an intermediate outcome. No trial has been large enough to prove that medication reduces dissection or death. The 2022 ACC/AHA guideline recommends an echocardiogram at diagnosis, again at 6 months and then yearly, and a beta blocker or ARB at the maximum tolerated dose. ARBs are contraindicated in pregnancy. Medication is prescribed by the cardiologist.

6. Aortic surgery, pregnancy and physical activity

  • Surgical threshold (ACC/AHA 2022): replace the aortic root and ascending aorta at a diameter ≥ 5.0 cm; reasonable at ≥ 4.5 cm with high-risk features (family history of dissection, rapid growth) when done by an experienced surgeon.
  • Pregnancy: the systematic review by Al-Thani and colleagues (Curr Vasc Pharmacol 2020) concluded that women with Marfan are at high risk of aortic dissection in pregnancy and that women with an aortic root of 41–45 mm should consider avoiding pregnancy. ACC/AHA 2022 recommends surgery before pregnancy if the root is > 4.5 cm. Genetic counselling and a cardiac assessment are needed before conception.
  • Activity (Milewicz 2021): avoid contact sports, heavy weightlifting and sustained isometric efforts or breath-holding, which cause blood-pressure spikes; exercise at low intensity, about 50% of maximum. The same applies to exercises that accompany bracing: gentle, steady breathing, no long holds.

7. Scoliosis in Marfan differs from idiopathic scoliosis

It is common: Sponseller and colleagues (J Bone Joint Surg Am 1995; 113 patients) found scoliosis in about 63% and spondylolisthesis in 6%. The Danish registry (Andersen, Orphanet J Rare Dis 2022; 407 patients vs 40,700 controls) found that 1 in 6 people with Marfan was registered with scoliosis (36.7 times the risk), 1 in 11 with a chest deformity and 1 in 6 with a foot deformity – mainly flat feet; many will need orthopaedic surgery during life.

Bracing studyDesignResult
Sponseller and colleagues, Spine 2000Retrospective, 24 braced children with Marfan, mean age at start 8.7, mean curve 29°Good in-brace correction (45%) but only 4/24 succeeded (17%); “success” = progression ≤ 5° and final curve ≤ 45°. Curves progressed a mean 6° per year; 16 children had or were advised to have surgery
Weiss and colleagues, 2012Case reportA young child with rapidly progressive scoliosis was braced early; the authors consider bracing worth trying in early-onset curves
Milewicz and colleagues, 2021Expert reviewConsider bracing in children with significant or rapidly progressing curves; consider surgery above about 40°

How to read the table: the two figures from the 2000 study measure different things – 45% is how much the curve was reduced while wearing the brace; 17% is the share of children whose curve was held until the end of treatment. Evidence on bracing in Marfan is scarce and old, with no randomized trials and no data on modern corrective brace designs. This is a research gap, not proof that bracing is useless.

8. Points to consider when making braces and orthoses for people with Marfan

This section is professional reasoning based on the disease mechanism and anatomy described above, not the result of clinical trials.

  • Lax connective tissue: the spine corrects well in the brace but also recurs easily when it is removed; follow-up should be closer than in idiopathic scoliosis, including after weaning.
  • Sunken, asymmetric chest: account for the chest shape when placing pressure pads; avoid pressing on the sunken sternum so as not to reduce chest volume further.
  • Heart: obtain a recent echocardiogram before bracing; a brace that compresses the chest and abdomen too tightly can affect breathing – coordinate with the cardiologist when the aortic root is markedly dilated.
  • Back pain or pain radiating to the legs: think of dural ectasia and spondylolisthesis and obtain imaging before blaming the brace.
  • Skin prone to striae: check pressure points regularly.
  • Flat feet with hindfoot valgus: foot orthoses or ankle-foot orthoses support the arch and control the heel; there are no high-quality studies specific to Marfan yet.

9. Summary of the strength of evidence

QuestionBest available evidenceLevel
Diagnostic criteriaInternational expert consensus, Ghent 2010Consensus, widely used
Beta blockers / ARBs slow aortic enlargementIndividual-patient meta-analysis, 7 trials, 1,442 peopleHigh (intermediate outcome)
Medication reduces dissection / deathCochrane 2017: 1 small trialLow
Aortic surgical thresholdACC/AHA 2022 guidelineFormal recommendation
Scoliosis bracing1 retrospective study of 24 children, case reportVery low
Foot orthosesNo Marfan-specific studiesNo evidence yet

Conclusion: Marfan is a whole-body disease; the risk of death is concentrated in the aorta and can be reduced by early diagnosis, medication and preventive surgery. Scoliosis in Marfan is common, progresses fast and resists bracing more than idiopathic scoliosis. The orthotist has two roles: recognising possible Marfan and referring for cardiology, and designing devices that respect each person’s connective tissue, chest shape and heart condition.

Videos from the Lê Hoàn YouTube channel

Áo Nẹp Chỉnh Hình
CÁC VẤN ĐỀ CỦA BÀN CHÂN BẸT

YouTube · Chân Tay Giả – Lê Hoàn

If your child has scoliosis together with a tall, slim build, long fingers, loose joints or a sunken chest, arrange a cardiology and genetics assessment and contact us for advice on the spine and bracing: +84 985 211 888 (phone / Zalo).

References

  1. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476–485. PMID: 20591885.
  2. Milewicz DM, Braverman AC, De Backer J, et al. Marfan syndrome. Nat Rev Dis Primers. 2021;7(1):64. PMID: 34475413.
  3. Groth KA, Hove H, Kyhl K, et al. Prevalence, incidence, and age at diagnosis in Marfan syndrome. Orphanet J Rare Dis. 2015;10:153. PMID: 26631233.
  4. Groth KA, Stochholm K, Hove H, Andersen NH, Gravholt CH. Causes of mortality in the Marfan syndrome (from a nationwide register study). Am J Cardiol. 2018;122(7):1231–1235. PMID: 30149886.
  5. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75(2):157–160. PMID: 7810492.
  6. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117–121. PMID: 16601194.
  7. Koo HK, Lawrence KAK, Musini VM. Beta-blockers for preventing aortic dissection in Marfan syndrome. Cochrane Database Syst Rev. 2017;11:CD011103. PMID: 29110304.
  8. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371(22):2061–2071. PMID: 25405392.
  9. Mullen M, Jin XY, Child A, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet. 2019;394(10216):2263–2270. PMID: 31836196.
  10. Pitcher A, Spata E, Emberson J, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022;400(10355):822–831. PMID: 36049495.
  11. Isselbacher EM, Preventza O, Black JH 3rd, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. J Am Coll Cardiol. 2022;80(24):e223–e393. PMID: 36334952.
  12. Sponseller PD, Hobbs W, Riley LH 3rd, Pyeritz RE. The thoracolumbar spine in Marfan syndrome. J Bone Joint Surg Am. 1995;77(6):867–876. PMID: 7782359.
  13. Sponseller PD, Bhimani M, Solacoff D, Dormans JP. Results of brace treatment of scoliosis in Marfan syndrome. Spine. 2000;25(18):2350–2354. PMID: 10984787.
  14. Andersen NH, Hauge EM, Baad-Hansen T, et al. Musculoskeletal diseases in Marfan syndrome: a nationwide registry study. Orphanet J Rare Dis. 2022;17:118. PMID: 35248143.
  15. Fattori R, Nienaber CA, Descovich B, et al. Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet. 1999;354(9182):910–913. PMID: 10489951.
  16. Oosterhof T, Groenink M, Hulsmans FJ, et al. Quantitative assessment of dural ectasia as a marker for Marfan syndrome. Radiology. 2001;220(2):514–518. PMID: 11477262.
  17. Shirley ED, Sponseller PD. Marfan syndrome. J Am Acad Orthop Surg. 2009;17(9):572–581. PMID: 19726741.
  18. Al-Thani H, Mekkodathil A, El-Menyar A. Management and outcomes of aortic dissection in pregnancy with Marfan syndrome: a systematic review. Curr Vasc Pharmacol. 2020;18(3):282–293. PMID: 30963974.
  19. Weiss HR, Werkmann M. Brace treatment in an infantile/juvenile patient with progressive scoliosis due to Marfan's syndrome. Scoliosis. 2012;7(Suppl 1):P5.

Do you or a loved one need advice?

Book an in-person assessment in Hanoi or send your file for a remote consultation. We reply within 24 hours.

Book a consultation